Purpose Loss of brain synapses is an early pathological feature of Alzheimer's disease. The current study assessed synaptic loss in vivo with positron emission tomography and an 18F-labelled radiotracer of the synaptic vesicle protein 2A, [18F]UCB-H. Methods Twenty-four patients with mild cognitive impairment or Alzheimer's disease and positive [18F]Flutemetamol amyloid-PET were compared to 19 healthy controls. [18F]UCB-H brain uptake was quantified with Logan graphical analysis using an image-derived blood input function. SPM12 and regions-of-interest (ROI) analyses were used for group comparisons of regional brain distribution volumes and for correlation with cognitive measures. Results A significant decrease of [18F]UCB-H uptake was observed in several cortical areas (11 to 18% difference) and in the thalamus (16% difference), with the largest effect size in the hippocampus (31% difference). Reduced hippocampal uptake was related to patients' cognitive decline (ROI analysis) and unawareness of memory problems (SPM and ROI analyses). Conclusions The findings thus highlight predominant synaptic loss in the hippocampus, confirming previous autopsy-based studies and a recent PET study with an 11C-labelled SV2A radiotracer. [18F]UCB-H PET allows to image in vivo synaptic changes in Alzheimer's disease and to relate them to patients' cognitive impairment.
Introduction
Loss of neurons and synapses constitutes a critical neuropathological feature of Alzheimer's disease (AD), combined with amyloid beta deposits and neurofibrillary tangles. Besides tau pathology, synaptic loss appears as the best correlate of cognitive decline in patients with mild cognitive impairment (MCI) and AD [1, 2] .
Post-mortem ultrastructural counts in MCI and AD revealed that the hippocampus and the entorhinal cortex are the most affected by synaptic loss [2] [3] [4] , followed by the cingulate gyrus and temporal cortex [4] . Basal forebrain is also a site of early neuronal loss in AD that can precede medial temporal involvement in prodromal AD [5] . Moreover, synaptic dysfunction, indexed by reduced level of expression of pre-and post-synaptic proteins such as synaptophysin or synaptic vesicle protein 2A (SV2A), is observed very early in AD. In MCI, it affects mainly the hippocampus, the temporal cortex [6, 7] , and posterior cingulate cortex [8] . In the dementia stage, synaptic dysfunction extends to parietal and frontal areas [6] .
Synaptopathy likely heralds the onset of cognitive decline in AD [3] . Given that impaired episodic memory is the initial symptom in the course of typical AD [9] and given the predominance of hippocampal synaptic loss in early AD [3] , it is likely that both are related. Memory deficits in AD may also relate to loss of cholinergic neurons in the basal forebrain.
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Recently, it has become possible to assess AD-related synaptic loss in vivo using PET imaging and tracers with nanomolar affinity for SV2A protein, such as [11C]UCB-J [10] , [11C]UCB-A [11] , and [18F]UCB-H [12] . SV2A is one of the membrane proteins of synaptic vesicles, contributing to the packaging and transport of neurotransmitters [13] . In AD, autopsy studies showed that the expression of SV2A protein is significantly diminished in the hippocampus and the neocortex [14] . Recently, [11C]UCB-J PET imaging was used to compare cerebral synaptic density between nine amyloidpositive AD patients (five MCI and four demented patients) and eight healthy controls [15] . Significant reduction of [11C]UCB-J was found specifically in the hippocampus and entorhinal cortex, with synaptic loss surviving partial volume correction only in the hippocampus. Chen et al. [15] combined patients and controls to observe a correlation between hippocampal synaptic density and a composite episodic memory score. These findings with SV2A-PET imaging open a new avenue for investigating the pathophysiology of AD in vivo [16] . Yet, 11C-labelled radiotracers are ill-suited for broad use, because the short half-life of the carbon-11 prevents transport of the tracer from production sites to remote PET scanning sites. So, a 18F-labelled radiotracer of SV2A protein (T 1/2 = 110 min), like [18F]UCB-H [12] , appears as very adequate for a broader use, including clinical practice [16] .
Consequently, the aim of the current study was to assess in vivo the regional synaptic loss in AD using [18F]UCB-H PET imaging. In previous works, we found that [18F]UCB-H uptake is blocked by pretreatment with levetiracetam in rodents and shows a testretest variability of 10.4% on the whole brain [12] , that there is negligible amount of radiometabolites in the rat brain and that the principal radiometabolite does not cross the blood brain barrier [17] , that the radioligand has good biodistribution and dosimetry properties for human PET imaging [18] , and that the radiotracer demonstrates the expected homogeneous distribution in the human brain [19] . Concretely, in this study, we compared regional cerebral uptake of [18F]UCB-H between amyloid-positive patients from the AD continuum and healthy older controls. Based on post-mortem findings [2] [3] [4] and on the results of the study using [11C]UCB-J PET in AD patients [15] , AD patients were expected to demonstrate predominant synaptic loss in the hippocampal structure and also synaptic reduction in the neocortex and the basal forebrain [2, 5, 8] . Correlation between SV2A-PET images and important measures of cognitive function (i.e., global cognitive decline, memory performance and awareness of everyday cognitive and memory functioning) were also examined.
Material and methods

Participants
Two groups of older participants were included in the study. In the first group, amyloid-positive patients from the AD continuum (Aβ-positive group, n = 25) were recruited from the Memory Clinic at the Liege University Hospital and were diagnosed based on current NIA-AA criteria [9, 20, 21] . As part of the initial diagnostic process, [18F]FDG-PET was used as a biomarker of neurodegeneration in some, but not all patients. Amyloid-β positivity was determined based on [18F]Flutemetamol-PET by qualitative visual inspection and by cortical standardized uptake value ratios (SUVR) above a quantitative threshold determined in a database of healthy older (HO) adults (SUVR T = SUVR (HO mean ) + 2 SUVR (HO SD ); cortical SUVR > 1.46). In this group, six patients met the criteria for MCI (MMSE between 26 and 30). The remaining 19 Aβ-positive patients were diagnosed with probable AD, with MMSE scores between 14 and 26 (mild stage, MMSE > 20, n = 15; moderate stage, MMSE ≤ 20, n = 4). The second group was composed of cognitively healthy older participants (CTRL, n = 21) (MMSE between 28 and 30). In the control group, amyloid-negativity was confirmed in eight participants, while there was no biomarker-related information for the others. Both groups were matched in terms of age, sex distribution, and education (Table 1) . Mild to moderate white matter lesion was not considered as an exclusion criterion.
Written informed consent was obtained from all participants according to the declaration of Helsinki. The study (EudraCT 2014-000286-50) was approved by the Ethics Committee of the Liege University Hospital.
Neuropsychological assessment
All participants performed a neuropsychological test known to be sensitive to early visual recognition memory deficits related to medial temporal lobe dysfunction (DMS48 [22] ). Global cognition was assessed with the MMSE. Everyday life cognitive functioning was assessed by means of informant-based reports and participants' reports with the Anosognosia Questionnaire-Dementia (AQ-D) that probes cognitive and behavioural changes [23] , and the Memory Awareness Rating scale-Memory Functioning Scale (MARS-FS) that addresses specifically memory impairment [24] . Inclusion of these scales was motivated by the finding that anosognosia could provide an early cognitive marker of AD [25] .
Cerebral image acquisition
Dynamic PET acquisitions were performed using a Siemens/ CTI (Knoxville, TN) ECAT HR+ PET scanner. 157.06 ± 8.96 MBq of [18F]UCB-H [26] were injected as an intravenous bolus (injected mass, 0.26 ± 0.21 μg). A thermoplastic mask was used to restrain motion during the acquisition. The timeframe of the dynamic PET was 6 × 10, 8 × 30, 5 × 120, and 17 × 300 seconds (total = 100 min). All PET images were reconstructed using filtered backprojection (Hann filter, 4.9 mm FWHM) including corrections for measured attenuation, dead time, random events, and scatter using standard software (ECAT 7.1, Siemens/CTI, Knoxville, TN). With these acquisition and reconstruction settings, the transaxial resolution in water is 6.5-7 mm in the brain volume (voxel size 2.57 × 2.57 × 2.43 mm 3 ). Blood samples were collected via a catheter inserted in an arm vein in 13 subjects (seven controls and six patients) 3, 5, 15, 45, 60, and 90 min postinjection in order to determine the plasmatic parent fraction with high performance liquid chromatography. A mean unchanged plasma fraction was calculated for each group and used for modelling [19] . Interestingly, mean unchanged plasma fraction did not differ between groups, F(1, 11) = 0.06, p = 0.80, and showed relatively little individual variability (coefficient of variation = 10.7%).
In addition, participants underwent a whole-brain quantitative MRI protocol on a 3T Siemens (Erlangen, Germany) Prisma scanner. Quantitative maps are obtained by combining images using different parameters sensitive to different tissue properties. Multiparameter mapping was based on multi-echo 3D fast low angle shot at 1 mm isotropic resolution [27] . This included three datasets with T1, proton density (PD), and magnetization transfer (MT)-weighted contrasts imposed by the choice of the flip angle (FA = 6°for PD & MT, 21°for T1) and the application of an additional off-resonance Gaussianshaped RF pulse for the MT-weighted acquisition. One AD patients (mild AD) could not undergo an MRI scan because she had a pacemaker and was excluded from the analysis (final Aβ-positive sample, n = 24).
Data are available from the corresponding author upon request.
Image processing
MRI multiparameter maps were processed with the VoxelBased Quantification (VBQ) toolbox [27] and SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK) to obtain notably a quantitative MT map as well as segmented images (grey matter, white matter, CSF, "other"), normalized to the standard MNI space using unified segmentation [28] . Modulated grey matter images, resized to 2 mm isotropic voxel size-like PET images, were smoothed with an isotropic Gaussian kernel of 8 mm of full-width at half maximum and analysed with voxel-based morphometry to identify atrophied regions in the AD group. Furthermore, spatial normalization parameters were used to normalize the PET images. The grey matter images across the study sample were used to create a grey matter mask for the statistical analyses.
[18F]UCB-H PET dynamic frames were corrected for motion without reslicing. The PET dynamic images were coregistered to the participant's structural MT image (taking the sum of frames between 2 and 30 min as source image). Then, because of the low resolution of the PET scan and because of our main interest in small structures like the hippocampus and the basal forebrain that are atrophied in early Alzheimer's disease [29] , the images were corrected for partial volume effects (PVE) using the "iterative Yang" voxel-wise method implemented in the PETPVC toolbox [30] , with grey matter, white matter, CSF and "other" as ROI masks. The ubiquitous distribution of SV2A in the brain makes very unlikely the identification of a "reference region" (with all its necessary characteristics) [31] for modelling the radiotracer distribution. Yet, in previous studies [15] , white matter was taken as reference region to measure binding potential. In our sample, visual inspection of MRI data using the agerelated white matter changes visual rating scale [32] by a neurologist blind to group status indicated white matter lesions in two controls and nine patients. Therefore, computation of binding potential using white matter was not appropriate for the current AD population. Moreover, the need of an arterial input function (AIF) is a heavy discomfort for the patient. An alternative method using image-derived input function was shown to be comparable to that using the AIF for [18F]UCB-H PET imaging [19] , even if the coefficient of variation for measurements was slightly increased.
So, the input function was derived from dynamic PET images [19] . Briefly, the method extracts time series of radiotracer activity in the carotid arteries [33] . The identification of voxels belonging to the carotids is based on the computation of the Pearson product-moment correlation coefficient between a "seeding region" and voxels in a mask containing the carotid. As, during the first 2 min, radioactivity is mainly localized in the vessels, inducing a large spill-out effect [33] , the signal was corrected for this spill-out effect using the geometric transfer matrix approach [34] . 1 For each group, the extracted signal was then corrected using the corresponding mean unchanged plasma fraction to obtain the input function used for modelling. Of note, for individuals with blood samples, we compared the distribution volume estimated using the group mean unchanged plasma fraction (Aβ-positive, 4.24 ± 0.98; control, 4.92 ± 1.02) to the distribution volume estimated using individual unchanged plasma fraction (Aβ-positive, 4.39 ± 1.15; control, 4.76 ± 1.56). Mean whole-brain distribution volume did not significantly differ between the two methods (Aβ-positive, Wilcoxon-matched pairs test Z = 0.31, p = 0.75; control, Z = 0.98, p = 0.32) and distribution volume across automated anatomical labelling atlas regions strongly correlated between methods (r = 0.99 in each group). Kinetic modelling using PVE-corrected dynamic PET data and image-derived input function was done with PMOD (Version 3.7, PMOD Technologies, Zurich, Switzerland). Logan graphical analysis was used to calculate the distribution volume (Vt) map of [18F]UCB-H in the brain. The t* for Logan analysis was 25 min.
Finally, the Vt map was normalized into the MNI space using transformation parameters obtained during structural MRI spatial normalization (2 mm isotropic voxel size). The PET data of two healthy controls had to be discarded, one because the carotids were not visible on the image and the other because the dynamic acquisition was aborted due to a technical problem (final control sample, n = 19).
Fifteen 
Statistical analyses
For SPM12 statistical analyses, the normalized PVE-corrected Vt maps were smoothed with an isotropic Gaussian kernel of 8 mm of full-width at half maximum. These Vt maps were entered in a two-sample t test contrasting images from the Aβ-positive group (n = 24) with those from the control group (n = 19). Parameters were estimated according to the general linear model at each voxel, using a grey matter mask. AD-related regional synaptic loss was tested by a linear contrast (Aβ-positive-controls) with a statistical threshold of p < 0.05 with a family-wise (FWE) correction for multiple comparisons at the voxel level (no minimal cluster size). Labelling of significant regions used the automated anatomical labelling atlas, and more specific identification of thalamic nuclei was based on an automated version of Morel's atlas of thalamic nuclei [35] . Furthermore, a sub-analysis comparing only mild AD patients (n = 14) with controls was conducted to examine changes in synaptic density in a group homogeneous in terms of clinical diagnosis criteria and severity. In the Aβ-positive group, SPM12 multiple regression models allowed to test for correlation between regional [18F]UCB-H distribution volume and each cognitive measure (MMSE, DMS48 proportion of correct responses, discrepancy scores between patients' and informants' assessments regarding cognitive and behavioural functioning, indicative of anosognosia) with a statistical threshold of p < 0.05 FWE-corrected at the voxel level (no minimal cluster size).
In addition, hypotheses about regional loss of synapses were assessed by comparing the mean Vt values extracted from the unsmoothed normalized PVE-corrected Vt maps of the two groups in 10 regions of interest (ROIs) (averaged across both hemispheres): hippocampus, parahippocampal gyrus, lateral parietal cortex, posterior cingulate cortex, lateral prefrontal cortex, lateral temporal cortex, occipital cortex, thalamus (ROIs built from automated anatomical labelling atlas), and basal forebrain Ch1-3 and Ch4 with stereotaxic probabilistic maps created by microscopic delineations in human postmortem brains [36] . Using Statistica (StatSoft, Inc.), group differences in mean Vt values in the ROIs (considering mainly the whole Aβ-positive group, and also the mild AD subgroup) were assessed with an analysis of variance (ANOVA) with group as between-subject variable and regions as within-subject variable, with an alpha level of 0.05. Posthoc group comparison for each ROI was computed with Student t tests. Additionally, mean Vt values were extracted from the centrum semiovale and the cerebellum grey matter as "control" regions [15] . For those regions, group differences were tested with Student t test (p < 0.05). Effect size of group differences was measured with Cohen's d corrected for sample size inferior to 50. Pearson correlations between ROI Vt values and cognitive measures were finally computed, considering variability in the Aβ-positive group only. Given the modulating effect of education on cerebral changes, for instance on cholinergic activity [37] , Pearson correlations between ROI Vt values and education were also assessed in the Aβ-positive group.
Voxel-based morphometry in SPM12 allowed to compare groups in terms of atrophy with a statistical threshold of p < 0.05 with a FWE correction for multiple comparisons at the voxel level. In the Aβ-positive group, grey matter density was also extracted in the hippocampal ROI and correlated to 
Results
Neuropsychological assessment
The Aβ-positive group demonstrated visual recognition memory impairment (Table 1) . Both participants and informants reported more cognitive and behavioural changes, as well as poorer everyday life memory functioning in the Aβ-positive compared to the control group. As a group, Aβ-positive patients were aware of their cognitive difficulties, as suggested by average participant-informant discrepancy scores that did not differ from controls' scores. However, individual variability was large in the patient group, with scores ranging from − 0.99 (i.e., overestimation of memory problems) to 1.36 (i.e., underestimation of memory problems) for the MARS-FS. Fig. 1 SPM12 results AD patient (n = 14), the sub-analysis showed reduced synaptic density in the right superior temporal gyrus (p < 0.05 FWEcorrected), and, at a more lenient threshold, in the right hippocampus and right middle frontal gyrus (p < 0.10 FWE-corrected) (Online Resource 1). SPM12 group comparison using non-PVE corrected images showed less significant difference (the right hippocampus -MNI coordinates 16-12-16, k = 12-showed reduced Vt values at an uncorrected threshold of p < .001).
In order to further test hypotheses about regions showing synaptic loss in AD, mean Vt values were compared between groups in several ROIs selected according to neuropathological data reported in the introduction. Mean Vt values per ROIs in each group are reported in Table 3 , together with the effect size of the group difference and the percentage of uptake reduction in the Aβ-positive group compared to the control group. The ANOVA comparing [18F]UCB-H values as a function of group and ROIs confirmed the significant reduction of synaptic density in Aβ-positive patients [main effect of group, F(1, 41) = 7.6, p < 0.01] and showed a main effect of regions [F(9, 369) = 103.6, p < 0.001]. The significant group by region interaction [F(9, 369) = 2.1, p < 0.05] indicated that Aβ-positive-related synaptic loss is more pronounced in some regions than others. To explore the interaction, follow-up t tests assessed group differences for each region (Table 3 ). The largest significant group difference concerned the hippocampus, with a large effect size (Cohen's d = 1.24). All other ROIs, except the basal forebrain Ch4 and the posterior cingulate region, also showed significant group differences. With regard to "control" regions, [18F]UCB-H values did not differ between groups. The distribution of Vt values in each ROI as a function of group can be seen in Fig. 2 .
When comparing ROI-based Vt values between mild AD only and healthy controls, we observed significant group differences in the hippocampus (large effect; d = 1.29), parahippocampal cortex, thalamus, parietal and temporal cortex (Online Resource 2). Finally, when Vt values were extracted from non-PVE-corrected PET images, significant reduction of synaptic density in Aβ-positive patients was found in the hippocampus, basal forebrain Ch1-3, parahippocampal cortex and thalamus, with the largest group difference in the basal forebrain Ch1-3 and hippocampus (d = 0.82 and 0.80 respectively, see Online Resource 3). With this radiotracer and with our PET camera, patients' hippocampal uptake values were smaller after PVE correction compared to noncorrected values, whereas values were more stable in other regions, like the parahippocampal region. Although infrequent, such effect of PVE correction has already been described for the hippocampus [38] , pointing to a complex spill-over effect in normal and pathological ageing.
Voxel-based morphometry analyses comparing grey matter density between groups revealed significant atrophy in the Aβ-positive patients in the hippocampus bilaterally and the left inferior frontal cortex (Table 4) 
Discussion
This study reports the topography of synaptic loss in vivo in early AD using PET and [18F]UCB-H radiolabelled ligand that binds to SV2A proteins. The main finding is strong evidence of synaptic loss in the hippocampus in amyloid-positive patients from the AD spectrum, with most patients in the early stages of the disease. This result was observed consistently in the whole sample, as well as in mild AD only, with and without PVE correction. SV2A-PET imaging thus allowed to capture the early and prominent hippocampal loss of synapses in AD that was consistently demonstrated in post-mortem analyses [2, 3, 6] . This is also in line with a recent study on SV2A-PET imaging in AD using [11C]UCB-J [15] which demonstrated reduced tracer uptake in the hippocampus. The hippocampus was significantly atrophied in Aβ-positive patients and [18F]UCB-H uptake and grey matter density correlated in the hippocampus (even more so when PET images were corrected for PVE). Kepe et al. [39] found a similar strong correlation between hippocampal atrophy and serotonin 1A PET data in AD, but showed that PVE had only limited effects on the significant decrease of tracer binding in AD. So, even if the accuracy of PVE-correction for [18F]UCB-H should be assessed, reduced synaptic density after partial volume correction may not merely reflect atrophy. The correlated signal across both measures could stem from a similar cause such as neuronal death [39] . Indeed, although mildly impaired, the Aβ-positive patients were already symptomatic, and so had accumulated substantial neuropathological changes that can be seen through different neuroimaging measures. In order to assess the chronological unfolding of pathological events, for instance synaptic loss versus atrophy, it would be necessary to perform these measures longitudinally in asymptomatic individuals at high risk of developing AD. Moreover, voxel-wise group comparisons showed additional reduced grey matter density in the prefrontal cortex, whereas additional diminished synaptic density was found in the thalamus. This suggests that [18F]UCB-H measures provide complementary topographical mapping of loss of synapses beyond volume loss.
Derived from [18F]UCB-H uptake, Aβ-positive-related hippocampal reduction in synaptic density was estimated at 26.9% in the right anterior hippocampus when considering the cluster showing significant difference in SPM analyses or at 30.9% when considering the values extracted from the hippocampal ROI. Counts of synapses at autopsy indicated a rate of 44% and 55% of loss in the dentate gyrus and CA1 subfield of the hippocampus respectively in mildly-to-severely demented AD patients compared to healthy older adults [2] . As for MCI patients, they had 13% and 18% fewer synapses in dentate gyrus and CA1 subfield respectively [2] . The rate of 26.9% of reduced hippocampal synaptic density obtained with SV2A-PET imaging plausibly lies between autopsybased values for MCI and AD patients and likely characterizes early AD stages. It is also very consistent with the 28% reduction in hippocampal Vt reported by Chen et al. [15] with [11C]UCB-J in a small Aβ-positive population. In addition to the prominent reduction of synaptic density in the hippocampus, ROI-based group comparisons of [18F]UCB-H distribution volume revealed widespread synaptic decline across the neocortex [3, 4] and in some subcortical nuclei in AD patients, including the basal forebrain Ch1-3. Although it is well-established that basal forebrain neurons are very vulnerable to early AD [5] , the impact of AD on synapses of this region was never previously reported in vivo. Of note, the reduction of synaptic density was mainly observed in regions Ch1-3, which contains notably the medial septal nucleus and the diagonal band of Broca, that project to the hippocampal complex [40] , but less so in basal forebrain region Ch4, containing nucleus basalis of Meynert and projecting to the amygdala and most cortical regions [36] . Given that loss of cholinergic neurons in AD concerns Ch4 more than Ch1-3 [40] , the current findings may rather reflect disconnection of basal forebrain-hippocampal circuit. The voxel-wise analysis also pointed to an important involvement of the thalamus in synaptic loss due to AD. Whereas Chen et al. [15] reported reduced [11C]UCB-J uptake in the pulvinar nucleus, the thalamic areas showing reduced synaptic density in the current Aβ-positive sample are mainly the dorsomedial nucleus and anterior nucleus. These nuclei are connected to the entorhinal cortex and hippocampus respectively [41] , as well as to the prefrontal cortex [42] . Thus, the findings of reduced [18F]UCB-H distribution volume in the hippocampus, basal forebrain, and anterior/dorsomedial thalamus suggests a particular vulnerability of medial temporalfrontal lobe circuits to early synaptic loss in the course of AD.
In the current design, [18F]FDG-PET was used as a biomarker of neurodegeneration to increase our probability of AD diagnosis in some patients. At visual inspection, a typical pattern of hypometabolism in the temporoparietal areas and posterior cingulate cortex was observed. Interestingly, in 15 Aβ-positive patients who underwent the [18F]FDG-PET scan less than four years before the current study, no relationship was found between reduction of synaptic density and hypometabolism in the hippocampus and in the posterior cingulate cortex. Although this could indicate a chronological effect of the pathology due to the delay between the two PET explorations, this might also suggest that the two radiotracers measure different pathological mechanisms. Future studies using [18F]UCB-H and [18F]FDG PET imaging acquired at the same time period could inform about metabolic changes in brain networks that correlate to hippocampal synaptic loss.
Consistently with autopsy studies that related synaptic loss to cognitive impairment [3, 8] this correlation would indicate that cognitive decline in our group of mostly mildly impaired patients is associated with early sites of synaptic loss and neuronal death. In addition, ROI-based analyses indicated that visual recognition memory performance on DMS48 correlated with synaptic density in the parahippocampal gyrus (although not surviving correction for multiple comparisons). This finding suggests that PET imaging of SV2A protein allows a precise and specific mapping of behaviour and synaptic changes. Indeed, the DMS48 has been previously shown to be sensitive to dysfunction of the entorhinal and perirhinal cortices [22] .
Interestingly, there was a significant correlation between the degree of awareness of memory problems in patients and synaptic density in the hippocampus (surviving correction for multiple comparisons in both the voxel-wise and ROI-based analyses), posterior cingulate cortex, parahippocampal cortex, thalamus, and prefrontal cortex. The measure of anosognosia for memory problems varied largely in the current sample. The current finding suggests that patients who were less aware of their memory difficulties had reduced synaptic density in the hippocampus, as well as in connected regions. This circuit, critical for episodic memory [41] , would be important to remember everyday life instances of forgetfulness, so as to update knowledge about one's current memory status [43] . The correlation with the posterior cingulate cortex synaptic density is consistent with its integrative function by which the outcomes of retrieved self-knowledge and inference mechanisms are combined to reflect about one's own current memory abilities [44] . Again, the fact that different regions show a correlation between their [18F]UCB-H uptake values and distinct cognitive tasks suggest that SV2A-PET imaging could be a sensitive tool to localize relationships between synaptic loss and cognitive decline in a domain-specific manner.
One limitation of the current study is the fact that only eight control participants had a [18F]Flutemetamol PET scan to confirm the absence of amyloid deposit in their brain. This leaves open the possibility that some of the other control participants were actually amyloid positive. Despite the fact that this may have reduced the power to detect differences, it is noticeable that the Aβ-positive group was found to have reduced [18F]UCB-H uptake in the hippocampus in voxel-wise SPM analysis with the strictest statistical threshold. Another limitation is the delay separating [18F]FDG-PET and SV2A-PET imaging, but this comparison in a subgroup of patients was not the main goal of the current study. From a methodological viewpoint, the study confirms the possibility and the interest to use an image-based blood input function for the modelization of [18F]UCB-H brain distribution. Moreover, a validation of the most appropriate method for PVE correction still needs to be done for [18F]UCB-H, notably to assess whether the decrease of Vt values in the hippocampus and the stronger correlation with hippocampal atrophy after PVE correction reflect genuine results or are related to the correction method. Also, the use of the carotid image-derived input function should be validated in a larger sample including AD patients. Finally, we should emphasize that [18F]UCB-H provides a measurement of synaptic vesicle density that we use as a proxy to assess decreased synaptic density.
Altogether, the current study demonstrates that SV2A-PET imaging, here with [18F]UCB-H, allows to image in vivo synaptic changes in Aβ-positive patients and to relate them to cognitive impairment with regional specificity according to the cognitive domain. These findings confirm and extend those obtained with [11C]UCB-J. So, SV2A-PET imaging represents a new reliable tool to assess critical neuropathological changes during the lifetime of a patient, and the long-lived 18F-labelled tracer would allow its use in widespread research and clinical settings [16] . Moreover, it would provide a unique way to study synaptic loss in other dementias, like frontotemporal lobar degeneration. Finally, given that synaptic dysfunction precedes synapse loss and neuronal death in the cascade of pathogenic molecular changes leading to AD, novel therapeutic strategies may target reversible synaptic dysfunction and the benefit of such treatments would be ideally monitored by SV2A-PET scanning.
